RISA Labs Raises $11.1M Series A to Scale AI Operating System for U.S. Oncology Providers

New updates have been reported about RISA Labs.

RISA Labs has secured $11.1 million in Series A funding to accelerate national deployment of its AI operating system for oncology, a platform designed to streamline access, benefits verification, and prior authorization across cancer centers, health systems, specialty pharmacies, and infusion networks. The round was co-led by Cencora Ventures and Optum Ventures, with additional participation from Oncology Ventures, Z21 Ventures, and John Simon via his Ventureforgood vehicle. RISA’s system connects directly into oncology providers’ EMRs, payer and benefits infrastructures, and other systems of record, where a coordinated team of AI agents reads, reasons, and executes administrative tasks such as assembling documentation, submitting and tracking authorizations, and adapting to changing payer rules and forms in real time. Management positions this as a critical infrastructure layer for modern cancer care, where the complexity of multi-drug regimens, varied payer policies, and disease-specific requirements has outpaced the capacity of traditional manual workflows.

Operational data from early deployments at large U.S. oncology practices indicate substantial efficiency gains and financial impact: at one site, RISA reports that roughly 80% of administrative staff time tied to these workflows has been freed, denials have been cut by up to 40%, first-pass approval rates have reached 97.8%, and authorization backlogs have fallen from about eight days to submissions within 24 hours, with a roadmap to sub–two-hour turnaround. More than 20 full-time equivalents have been redeployed to higher-value work, effectively expanding capacity without equivalent headcount growth. Institutions configure and govern these workflows through BOSS Console, RISA’s command platform that allows tailoring of routing rules, documentation standards, and site-specific policies, while maintaining full audit trails for compliance and clinical oversight. CEO Kshitij Jaggi and CTO Kumar Shivang frame the company’s strategy as building the AI operating system for mission-critical institutions, starting with oncology and then extending to specialty pharmacy operations. Backers such as Cencora Ventures view the technology as increasingly essential to preserving access and throughput as cancer incidence rises, treatment options proliferate, and oncologist capacity remains constrained, positioning RISA for deeper integration across the oncology value chain in the coming year.